The bradycardia algorithm ACLS protocol is one of the most clinically important sequences in advanced cardiovascular life support because it forces providers to make fast, structured decisions when a patient's heart rate drops below sixty beats per minute and perfusion begins to fail. Understanding when to observe, when to give atropine, and when to escalate to transcutaneous pacing or dopamine separates competent ACLS providers from hesitant ones. This guide walks through every branch of the algorithm in the order you will use it.
According to the 2020 American Heart Association guidelines, which remain the basis for 2026 ACLS testing, bradycardia is formally defined as a heart rate under sixty beats per minute, but the algorithm only activates when that rate causes signs and symptoms of inadequate perfusion. The presence or absence of those symptoms is the single most important branch point you will encounter. Without symptomatic deterioration, the protocol becomes purely diagnostic and observational rather than pharmacological.
Recognizing symptomatic bradycardia at the bedside requires more than reading the monitor. You must integrate blood pressure trends, mental status, chest pain, dyspnea, capillary refill, and any sign of shock. A heart rate of fifty in a sleeping athlete is benign, while a rate of fifty-five in a hypotensive elderly patient is a medical emergency. The algorithm assumes you have already secured the airway, established IV access, applied continuous monitoring, and obtained a twelve-lead electrocardiogram before initiating therapy.
Atropine 1 mg IV remains the first-line drug for symptomatic bradycardia, repeated every three to five minutes up to a total of 3 mg. However, atropine is not universally effective and is specifically unreliable in heart transplant patients and high-degree atrioventricular block at the infranodal level. When atropine fails or is contraindicated, the algorithm directs you immediately toward transcutaneous pacing, a dopamine infusion of five to twenty micrograms per kilogram per minute, or an epinephrine infusion of two to ten micrograms per minute.
The 2026 emphasis on early electrical therapy reflects emerging evidence that delays in pacing for unstable bradycardia worsen neurological outcomes. Transcutaneous pacing should never be considered a last resort; it is a parallel option that can be initiated simultaneously with pharmacological therapy. Providers are increasingly trained to prepare the pacer pads during the first atropine dose so there is no equipment delay if escalation becomes necessary. Sedation and analgesia should be considered for conscious patients who tolerate capture, since the sensation is painful.
Beyond drugs and pacing, expert ACLS performance demands you identify and treat reversible causes using the H's and T's framework. Hypoxia, hypothermia, hyperkalemia, drug toxicity from beta blockers or calcium channel blockers, and acute coronary ischemia are common culprits behind symptomatic bradycardia. A focused history, point-of-care labs, and a twelve-lead ECG looking for inferior wall ST elevation should run in parallel with stabilization, not after it. For broader context on the protocols you will see tested, review the ACLS Study Guide: Complete 2026 Certification Prep with Algorithms, Drugs & Practice Tests for cross-algorithm integration.
This article is structured to take you from initial assessment through definitive post-stabilization care, with practice tiles, mnemonic checklists, and an FAQ targeting the exact testable details on the AHA written exam and megacode station. By the end you should be able to verbalize each step, recall every drug dose, and explain the indications for transvenous pacing referral to a cardiologist or intensivist.
Confirm heart rate under 60 bpm on continuous monitoring. Obtain a twelve-lead ECG, secure IV access, and assess oxygenation. Identify the underlying rhythm: sinus bradycardia, junctional escape, first-degree AV block, Mobitz I, Mobitz II, or third-degree AV block.
Determine whether the bradycardia is symptomatic. Look for hypotension, altered mental status, ischemic chest discomfort, acute heart failure, signs of shock, or syncope. If perfusion is adequate and the patient is asymptomatic, monitor and search for causes without immediate intervention.
If symptomatic, give atropine 1 mg IV push and repeat every three to five minutes to a maximum cumulative dose of 3 mg. Avoid atropine in heart transplant recipients and consider that it may worsen high-grade infranodal AV block by speeding sinus rate without improving conduction.
If atropine fails or is unlikely to succeed, begin transcutaneous pacing immediately while preparing alternative therapies. Set the rate at 60 to 80 bpm, increase milliamperage until electrical and mechanical capture are confirmed, and administer sedation as needed for patient comfort.
Start dopamine 5 to 20 mcg/kg/min or epinephrine 2 to 10 mcg/min as a bridge while arranging transvenous pacing or definitive cardiology consultation. Continue to treat reversible causes such as hyperkalemia, drug toxicity, or acute myocardial infarction throughout the entire process.
Recognizing symptomatic bradycardia is the most consequential decision point in the bradycardia algorithm ACLS workflow because every subsequent intervention hinges on whether the slow heart rate is actually causing harm. A heart rate of forty-eight in a marathon runner during sleep is physiologic and benign, while the same rate in a seventy-year-old with diabetes and acute chest pain demands aggressive intervention. The American Heart Association explicitly warns providers against treating numbers in isolation and instead emphasizes the clinical picture surrounding the rhythm strip.
The five cardinal signs of symptomatic bradycardia that ACLS instructors test repeatedly include hypotension with systolic pressure below ninety, acutely altered mental status, signs of shock such as cool clammy skin and delayed capillary refill, ischemic chest discomfort, and acute heart failure with pulmonary edema. The presence of any one of these features, in temporal association with the bradycardia, justifies activating the treatment arm of the algorithm rather than the watchful waiting arm. Documentation should explicitly link the symptom to the rhythm.
Rhythm identification matters because it predicts atropine responsiveness. Sinus bradycardia and first-degree AV block typically respond well to atropine because both involve the sinoatrial node or proximal AV node, where vagal tone dominates. Mobitz type I block, which often originates at the AV node, also tends to respond. In contrast, Mobitz type II and third-degree AV block typically originate below the AV node in the bundle of His or its branches, where atropine offers little benefit and may paradoxically worsen the ratio of conducted beats.
For wide-complex or infranodal blocks, the algorithm directs providers to bypass atropine and proceed directly to transcutaneous pacing or chronotropic infusions. This nuance is heavily tested on the written examination and frequently appears in megacode scenarios where the instructor wants to see whether you understand the anatomical basis of the block. Recognizing a wide QRS escape rhythm with a slow ventricular rate and complete AV dissociation should trigger immediate preparation for pacing rather than another round of atropine.
Hemodynamic assessment requires a manual blood pressure when possible, since automated cuffs frequently fail at very low heart rates or during pacing. Mental status should be evaluated using a standardized tool such as AVPU or GCS, and any acute decline from baseline qualifies as symptomatic. Mottled skin, weak peripheral pulses, oliguria, and lactic acidosis are downstream indicators that perfusion has failed. These findings often appear in patients whose bradycardia has persisted for hours before presentation.
Reversible causes deserve a deliberate review during the assessment phase. Hyperkalemia from missed dialysis sessions, beta blocker or calcium channel blocker overdose, digoxin toxicity, hypothyroidism, hypothermia, increased intracranial pressure, and acute inferior wall myocardial infarction with right coronary artery involvement are the most common reversible drivers. Each of these has a specific antidote or definitive therapy that must be initiated alongside the standard algorithm, and missing them is a frequent reason for failed resuscitation.
Finally, remember that pediatric and neonatal patients follow different bradycardia algorithms, and adult thresholds do not apply to them. Hypoxia is the leading cause of pediatric bradycardia, and ventilation often resolves the rhythm before any drug is needed. If the patient is pregnant or has a pacemaker already in place, additional considerations apply that may require obstetric or electrophysiology consultation. For a deeper dive into drug-specific decision points, the ACLS Drugs: Complete 2026 Guide to Medications, Doses, Indications & Algorithm Use covers each agent in detail.
Atropine 1 mg IV push is the first-line drug for symptomatic bradycardia in the 2026 ACLS guidelines, an increase from the older 0.5 mg dose that was abandoned because subtherapeutic doses can paradoxically worsen heart rate. Repeat the 1 mg dose every three to five minutes to a maximum cumulative dose of 3 mg. Flush each dose with 20 mL of saline and elevate the extremity to speed central delivery.
Atropine works by blocking vagal input to the sinoatrial and atrioventricular nodes, which means it is most effective for sinus bradycardia, first-degree block, and Mobitz type I. It should be avoided in heart transplant recipients because their denervated hearts lack vagal tone, and paradoxical sinus arrest has been reported. In Mobitz type II or third-degree block with wide QRS, atropine rarely works and should not delay pacing.
Dopamine is administered as a continuous IV infusion at 5 to 20 micrograms per kilogram per minute, titrated to patient response with a target heart rate that restores adequate perfusion, typically 60 to 80 bpm. At lower doses, dopamine acts primarily on beta-1 adrenergic receptors to increase chronotropy and inotropy, while at higher doses alpha-1 effects predominate, raising systemic vascular resistance and blood pressure.
Dopamine should be delivered through a central line whenever possible because peripheral extravasation can cause severe tissue necrosis requiring phentolamine reversal. Continuous blood pressure monitoring is essential, ideally with an arterial line. Common side effects include tachyarrhythmias, ventricular ectopy, nausea, and exacerbation of myocardial ischemia, so dopamine is generally a bridge to definitive transvenous pacing rather than a long-term therapy.
Epinephrine infusion at 2 to 10 micrograms per minute is an alternative to dopamine, especially when severe hypotension accompanies the bradycardia or when dopamine has failed to produce adequate capture. Mix one milligram of epinephrine in 250 mL of normal saline to yield a 4 mcg/mL concentration, then titrate to heart rate and blood pressure targets while watching closely for ventricular ectopy.
Epinephrine stimulates beta-1, beta-2, and alpha-1 receptors, producing potent chronotropy, inotropy, and vasoconstriction. This makes it especially useful in mixed bradycardia and shock states. Like dopamine, it should be infused through a central line if available, and the patient should be monitored for ischemic chest pain, dysrhythmias, and severe hypertension if the infusion rate climbs too high during titration to target heart rate.
The single most common failure on the bradycardia megacode station is delayed initiation of transcutaneous pacing while waiting for additional atropine doses to take effect. ACLS instructors specifically watch for whether the candidate calls for pacer pads as soon as the first dose of atropine fails, not after the third. Verbalize your plan to pace early, especially when you see a wide-complex escape rhythm.
Transcutaneous pacing is the most reliable bridge therapy in the bradycardia algorithm ACLS sequence when atropine has failed or is unlikely to work, yet it remains the intervention that providers fumble most often in simulation and real practice. Proper technique requires familiarity with the specific defibrillator model on your unit, correct pad placement, appropriate rate and output selection, and confirmation of both electrical and mechanical capture before declaring success. Skipping any of these steps leads to false confidence in a non-perfusing rhythm.
Pad placement options include anterior-posterior, with one pad over the left precordium and the other on the left mid-back below the scapula, or anterior-lateral, with pads on the right upper chest and left lateral chest wall. The anterior-posterior configuration is preferred for pacing because it sandwiches the heart between the two electrodes, lowering the milliamperage required for capture and reducing pectoral muscle stimulation. Hair should be clipped, not shaved, and the skin must be dry to ensure proper adhesion.
Initial rate selection on the pacer is typically 60 to 80 bpm, which provides adequate cardiac output without provoking ischemia in patients with coronary artery disease. The provider then increases the milliamperage output in 5 to 10 mA increments from 0 until capture is achieved, usually between 50 and 100 mA in adults. Some providers prefer to start at 70 mA and titrate downward to find threshold, which is acceptable as long as capture is confirmed and maintained throughout the procedure.
Electrical capture is identified by a wide QRS complex following each pacer spike, while mechanical capture requires confirmation of a palpable pulse synchronous with the pacer spikes, typically at the femoral or right brachial artery to avoid mistaking muscle twitching for arterial pulsation. Pulse oximetry waveform and arterial line tracings provide additional objective confirmation. Without mechanical capture, the patient is still effectively in pulseless electrical activity despite the visually convincing pacer spikes.
Patient comfort during pacing is a frequently neglected priority. The sensation of transcutaneous pacing is described by conscious patients as painful, with each electrical impulse causing thoracic muscle contraction. Sedation with intravenous midazolam 1 to 2 mg and analgesia with fentanyl 25 to 50 micrograms is appropriate for awake patients, titrated to comfort while preserving airway reflexes and blood pressure. Excessive sedation can drop blood pressure further and complicate the picture.
Common pacing pitfalls include setting the output too low to achieve capture, mistaking pacer spike artifact for true capture, missing intermittent loss of capture during patient movement, and failing to switch from demand to fixed mode when patient intrinsic activity is interfering. Continuous monitoring, regular reassessment, and documentation of capture every five minutes are essential. If transcutaneous pacing fails to maintain capture or the patient requires prolonged pacing, transvenous pacing under fluoroscopy becomes the next step.
Once capture is confirmed and hemodynamics improve, the focus shifts to definitive care, which usually means arranging transfer to a cardiac intensive care unit and consulting cardiology or electrophysiology for transvenous or permanent pacemaker placement. Throughout the entire process, the team should continue to investigate and address reversible causes such as hyperkalemia, drug toxicity, or acute coronary syndromes. Pacing controls the symptom but rarely fixes the underlying disease that triggered the bradycardia.
Post-stabilization care after a symptomatic bradycardia event determines whether the patient maintains the gains achieved by atropine, pacing, or chronotropic infusion. The immediate priority once a stable heart rate has been restored is to identify and treat the underlying cause, because pacing or drug therapy is purely supportive. Without addressing root causes, bradycardia will recur as soon as the bridge therapy is withdrawn. A structured handoff to cardiology and critical care is mandatory.
Laboratory workup should include a complete metabolic panel with potassium, magnesium, calcium, and renal function, along with a troponin to evaluate for myocardial ischemia, thyroid stimulating hormone to rule out hypothyroidism, and a drug screen if toxic ingestion is suspected. A digoxin level is appropriate if the patient takes digoxin, and serum drug levels for beta blockers or calcium channel blockers may be obtained in suspected overdose cases. Arterial blood gas analysis assesses oxygenation, ventilation, and acid-base status.
The twelve-lead ECG should be repeated after stabilization to look for evolving inferior wall ST-segment elevation, since right coronary artery occlusion is a common cause of sinus bradycardia and AV block. If ST elevation is present, the patient is a candidate for emergent cardiac catheterization with primary percutaneous coronary intervention, and the cardiac catheterization laboratory should be activated even while pacing is ongoing. Time to reperfusion remains the strongest predictor of survival in this population.
Transvenous pacing should be arranged for any patient with persistent symptomatic bradycardia that requires ongoing electrical support beyond the first hour of presentation. Transcutaneous pacing is uncomfortable and reliability declines over time as skin impedance changes and pad adhesion weakens. Transvenous pacing provides more reliable capture, allows the patient to be sedated less, and serves as a longer-term bridge to permanent pacemaker placement when the underlying conduction system disease is irreversible.
Indications for permanent pacemaker placement include symptomatic sinus node dysfunction, second-degree AV block Mobitz type II, third-degree AV block in adults, chronotropic incompetence, and certain forms of bundle branch block with syncope. The decision for permanent implantation is made by cardiology in consultation with electrophysiology and depends on the reversibility of the underlying cause. Patients who develop bradycardia from acute myocardial infarction may regain normal conduction after reperfusion and not require a permanent device.
Medication review is essential during the post-stabilization period. Many cases of symptomatic bradycardia are precipitated by inappropriately dosed beta blockers, calcium channel blockers, digoxin, amiodarone, ivabradine, or other rate-controlling agents. A clinical pharmacist should review the patient's entire medication list to identify culprits, recommend dose reductions or substitutions, and educate the patient about avoiding combinations that potentiate bradycardia. Discharge counseling should include warning signs that require immediate return to the emergency department.
Finally, family education and goals-of-care discussions are appropriate for any older adult with recurrent symptomatic bradycardia, especially if the cause is degenerative conduction system disease in a frail patient. Some patients may decline pacemaker implantation in favor of comfort-focused care, and the ACLS provider should be comfortable facilitating these conversations alongside palliative care colleagues. For comprehensive guideline updates that govern these decisions, see the ACLS Guidelines 2026: Complete AHA Update on Algorithms, Drugs, CPR Quality & Post-Arrest Care.
Practical exam preparation for the bradycardia algorithm ACLS station requires deliberate repetition of the decision tree until you can verbalize each step without hesitation. Most candidates fail not because they lack knowledge but because they freeze under the pressure of the megacode environment, hesitate between atropine and pacing, or skip the symptom assessment entirely. Talking through the algorithm out loud during practice sessions, ideally with a peer or instructor, is the single most effective preparation technique reported by recently certified providers.
Mnemonics help anchor key details during the high-stress test environment. The phrase ABCDE for bradycardia stands for Assess perfusion, Begin atropine, Call for pacer, Dopamine or epinephrine drip, and Expert consultation. Keeping this sequence in mind prevents you from skipping steps or reordering them under pressure. Some candidates prefer the AHA wall card mnemonic, which uses a vertical decision tree starting with the question, is the bradycardia causing hemodynamic compromise.
Drug doses are the most frequently missed items on the written exam. Memorize atropine 1 mg IV every three to five minutes up to 3 mg total, dopamine 5 to 20 mcg/kg/min infusion, and epinephrine 2 to 10 mcg/min infusion. Write these doses on flashcards along with the indications and contraindications for each, and review them daily for the two weeks preceding your test date. Spaced repetition apps are particularly effective for this kind of memorization.
Rhythm strip recognition deserves dedicated practice time. Spend at least three hours working through example strips of sinus bradycardia, junctional escape rhythm, first-degree AV block, Mobitz type I Wenckebach, Mobitz type II, third-degree block, and idioventricular rhythm. Identifying each rhythm in under five seconds and correctly predicting atropine responsiveness is the test of true mastery. Online rhythm strip generators and printed flashcards both work well for this skill.
For megacode preparation, walk through scenarios with a partner who plays the role of the team leader, recorder, and code nurse so you can practice closed-loop communication. Verbalize every observation, drug order, and reassessment, and explicitly ask for the pacer pads as soon as the first atropine dose is given. Instructors give credit for anticipatory thinking, so demonstrating that you have already prepared for the next step before the previous one fails will improve your score significantly.
Time management on the written portion is rarely a problem since the exam is generously timed, but candidates frequently second-guess themselves and change correct answers under doubt. Trust your first instinct unless you have a specific reason to revise. Read each question stem twice, identify the keyword such as symptomatic or stable, and eliminate distractors that violate the algorithm rather than searching for the perfect answer among similar options. Most ACLS questions reward straightforward algorithmic thinking.
On test day, arrive early, eat a balanced meal, hydrate moderately, and avoid excessive caffeine that may worsen test anxiety. Bring two forms of identification and any required documentation. The bradycardia algorithm is one of six major algorithms tested, so do not over-prepare on this single topic at the expense of tachycardia, cardiac arrest, post-arrest care, acute coronary syndromes, and stroke. A balanced study schedule produces the highest pass rates.